24th International Prostate Cancer Update

Vail, CO US

February 19, 2014 to February 22, 2014

Overview

Patterns of care in prostate cancer (PCa) have changed tremendously in the past 20 years, altering the way patients with this tumor present and how they are evaluated before and after diagnosis. With the use of new and combined treatments, the frequency and variety of complications have differed from those previously reported. Advances have been made in PCa imaging, biopsy methodology, in understanding causative factors and disease, in treatment-related quality of life, and in predicting the behavior of individual tumors using risk strata. Despite these advances, no consensus has emerged regarding the optimal treatment for the most common patient with PCa.

There is a need for oncologists, urologists, and nurses to understand the rationale behind targeted therapy for the treatment of advanced PCa, and how trial entry could improve the efficacy of drugs and decrease the toxicity. This activity seeks to educate urologists and other healthcare professionals about the latest advances in the prevention, screening, and treatment of PCa. The International Prostate Cancer Update (IPCU) educational planning committee has identified the following educational gaps between recent research in PCa and its integration into professional practice at the international, national, and community levels:

Current best practices in prevention and screening of PCa
Promising therapies, issues, and economic concerns in the treatment of local disease
Role of newly available therapies in 2014
Emerging treatment options for localized, advanced, and castration-resistant PCa

Target Audience

oncologists, urologists, and nurses

Additional information

Contact

Name:

Linda Caples, MBA

Phone Number:

+1 (414) 955-7103

Email:

cme@mcw.edu

Course summary

Available credit:

15.25 AMA PRA Category 1 Credit(s)™
AMA PRA Category 1 Credit(s)™
15.25 Hours of Participation
Hours of Participation credit.

Course opens:

02/17/2014

Course expires:

12/30/2016

Event starts:

02/19/2014 - 8:00am CST

Event ends:

02/22/2014 - 5:00pm CST

Cost:

$0.00

Add to calendar:

Vail Cascade

1300 Westhaven Drive

Vail, CO 81657

United States

To make your hotel reservation, please contact the Cascade at 800-420-2424 and request the Reservations Department. Mention that you are attending the International Prostate Cancer Update Meeting.

Accommodations

Vail Cascade
1300 Westhaven Drive
Vail, Colorado 81657

To make your hotel reservation, please contact the Cascade at 800-420-2424 and request the Reservations Department.

A block of rooms has been reserved at the Cascade for the nights of Wednesday, February 19, through Saturday, February 22, at discounted rates, (see list below), single or double occupancy, plus applicable taxes and fees. A limited number of rooms are available for this group, so reservations will be accepted on a first-come, first-served basis.

Room	Rates
Main Lodge	$275.00
Deluxe Rooms	$324.00
Mountain Grand Fireplace	$344.00
Cascade Suites	$474.00-$514.00

To receive your discounted rate, please reference the group code "International Prostate Cancer Update." Full payment is required on the date the reservation is made. Full payment for room and tax is refunded if notice is received no later than 30 days in advance of the confirmed arrival date. No shows and early departure/late arrivals will be charged for their full reservation.

Travel

It is recommended that attendees fly into either Denver International Airport (code "DEN") or Eagle County Airport (code "EGE").

The Cascade is located approximately 100 miles west of Denver via Interstate 70 and approximately 35 miles east of the Eagle County Airport via US Highway 6 and Interstate 70.

Ground Transportation

Ground transportation reservations from the airport to the hotel may be made directly through Colorado Mountain Express.

Phone: 800-525-6363
Fax: 970-926-9686
Online: ridecme.com

FACULTY

Program Chair

E. David Crawford, MD
University of Colorado, Denver
Aurora, Colorado

Program Committee

James A. Eastham, MD Memorial Sloan-Kettering Cancer Center New York, NY	Alan W. Partin, MD, PhD Johns Hopkins Medical Institutions Baltimore, MD
Leonard G. Gomella, MD Thomas Jefferson University Philadelphia, PA	Daniel P. Petrylak, MD Yale Cancer Center New Haven, CT
M. Scott Lucia, MD University of Colorado, Denver School of Medicine Aurora, CO	Neal D. Shore, MD Atlantic Urology Clinics, LLC Myrtle Beach, SC

Invited Faculty

Sean P. Collins, MD, PhD Georgetown University Hospital Washington, DC	Peter F. A. Mulders, MD, PhD Radboud University Medical Center Nijmegen, The Netherlands
James A. Eastham, MD Memorial Sloan-Kettering Cancer Center New York, NY	Alan W. Partin, MD, PhD Johns Hopkins Medical Institutions Baltimore, MD
L. Michael Glodé University of Colorado, Denver School of Medicine Aurora, CO	Daniel P. Petrylak, MD Yale Cancer Center New Haven, CT
Leonard G. Gomella, MD Thomas Jefferson University Philadelphia, PA	Peter A. Pinto, MD U.S. National Institutes of Health Bethesda, MD
Aaron E. Katz, MD Winthrop-University Hospital Mineola, NY	Matt T. Rosenberg, MD Urologic Health Foundation Jackson, Michigan
Thomas E. Keane, MBBCh Medical University of South Carolina Charleston, SC	Neal D. Shore, MD Atlantic Urology Clinics, LLC Myrtle Beach, SC
Phillip J. Koo, MD University of Colorado, Denver School of Medicine Aurora, CO	Nelson N. Stone, MD Mount Sinai School of Medicine Mount Sinai School of Medicine New York, NY
M. Scott Lucia, MD University of Colorado, Denver School of Medicine Aurora, CO	Priya N. Werahera, PhD University of Colorado, Denver School of Medicine Aurora, CO
Brian J. Moran, MD Chicago Prostate Center Westmont, IL